Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-13 4:15 pm Purchase |
2024-12-31 | 13G | Rapport Therapeutics, Inc. Common Stock RAPP |
Third Rock Ventures V L.P. | 7,135,233 19.500% |
7,135,233 (New Position) |
Filing History |
| 2024-11-14 5:13 pm Purchase |
2024-09-30 | 13G | Rapport Therapeutics, Inc. Common Stock RAPP |
ARCH Venture Fund XII, L.P. | 3,728,738 10.200% |
3,728,738 (New Position) |
Filing History |
| 2024-11-14 3:11 pm Purchase |
2024-09-30 | 13G | Rapport Therapeutics, Inc. Common Stock RAPP |
Cormorant Asset Management LP | 2,940,921 8.040% |
638 (+0.02%) |
Filing History |
| 2024-11-13 12:26 pm Purchase |
2024-11-14 | 13G | Rapport Therapeutics, Inc. Common Stock RAPP |
Capital International Investors | 2,602,529 7.100% |
2,602,529 (New Position) |
Filing History |
| 2024-11-12 10:34 am Purchase |
2024-11-08 | 13G | Rapport Therapeutics, Inc. Common Stock RAPP |
FMR CORP | 5,486,468 14.999% |
503,117 (+10.10%) |
Filing History |
| 2024-10-18 5:23 pm Purchase |
2024-09-30 | 13G | Rapport Therapeutics, Inc. Common Stock RAPP |
JOHNSON & JOHNSON JNJ |
2,498,051 6.800% |
2,498,051 (New Position) |
Filing History |
| 2024-07-10 10:10 am Purchase |
2024-07-09 | 13G | Rapport Therapeutics, Inc. Common Stock RAPP |
FMR CORP | 4,983,351 13.624% |
4,983,351 (New Position) |
Filing History |
| 2024-06-24 9:00 pm Sale |
2024-06-13 | 13G | Rapport Therapeutics, Inc. Common Stock RAPP |
GOLDMAN SACHS GROUP INC GS |
1,285,188 3.500% |
-1,380,494 (-51.79%) |
Filing History |
| 2024-06-21 4:52 pm Purchase |
2024-06-11 | 13G | Rapport Therapeutics, Inc. Common Stock RAPP |
GOLDMAN SACHS GROUP INC GS |
2,665,682 7.500% |
2,665,682 (New Position) |
Filing History |
| 2024-06-20 4:01 pm Purchase |
2024-06-10 | 13G | Rapport Therapeutics, Inc. Common Stock RAPP |
Cormorant Asset Management LP | 2,940,283 8.040% |
2,940,283 (New Position) |
Filing History |
| 2024-06-14 3:59 pm Purchase |
2024-06-10 | 13D | Rapport Therapeutics, Inc. Common Stock RAPP |
Sofinnova Venture Partners XI L.P. | 1,951,562 5.500% |
1,951,562 (New Position) |
Filing History |